We are working on a number of biologics programs to target key pathways implicated in metabolic complications and different types of cancer. We have quickly established our project portfolio with robust molecules and strong IP positions. Our pipeline focus is consistent with our mission and we believe these molecules will help us achieve our goal of becoming one of the most competitive biotech companies in these therapeutic areas.